Thompson JA - Search Results

1

T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.

Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee C. Chapuis AG, et al. Among authors: thompson ja. J Clin Oncol. 2016 Nov 1;34(31):3787-3795. doi: 10.1200/JCO.2015.65.5142. J Clin Oncol. 2016. PMID: 27269940 Free PMC article.

2

Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma.

Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins C, Lange PH, Bush WH Jr, Benz LA, Fefer A. Thompson JA, et al. J Clin Oncol. 1992 Jun;10(6):960-8. doi: 10.1200/JCO.1992.10.6.960. J Clin Oncol. 1992. PMID: 1588376 Clinical Trial.

3

Enhancement by interleukin 4 of interleukin 2- or antibody-induced proliferation of lymphocytes from interleukin 2-treated cancer patients.

Treisman J, Higuchi CM, Thompson JA, Gillis S, Lindgren CG, Kern DE, Ridell SR, Greenberg PD, Fefer A. Treisman J, et al. Among authors: thompson ja. Cancer Res. 1990 Feb 15;50(4):1160-4. Cancer Res. 1990. PMID: 2153452

4

Influence of dose and duration of infusion of interleukin-2 on toxicity and immunomodulation.

Thompson JA, Lee DJ, Lindgren CG, Benz LA, Collins C, Levitt D, Fefer A. Thompson JA, et al. J Clin Oncol. 1988 Apr;6(4):669-78. doi: 10.1200/JCO.1988.6.4.669. J Clin Oncol. 1988. PMID: 3258631

5

Potential uses of interleukin 2 in cancer therapy.

Cheever MA, Thompson JA, Peace DJ, Greenberg PD. Cheever MA, et al. Among authors: thompson ja. Immunobiology. 1986 Sep;172(3-5):365-82. doi: 10.1016/S0171-2985(86)80118-8. Immunobiology. 1986. PMID: 3492434

6

Interleukin 2 (IL 2) administered in vivo: influence of IL 2 route and timing on T cell growth.

Cheever MA, Thompson JA, Kern DE, Greenberg PD. Cheever MA, et al. Among authors: thompson ja. J Immunol. 1985 Jun;134(6):3895-900. J Immunol. 1985. PMID: 3872906

7

Interleukin-2 administered in vivo induces the growth and augments the function of cultured T cells in vivo.

Cheever MA, Thompson JA, Kern DE, Greenberg PD. Cheever MA, et al. Among authors: thompson ja. J Biol Response Mod. 1984 Oct;3(5):462-7. J Biol Response Mod. 1984. PMID: 6334133

8

Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.

Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PD. Yee C, et al. Among authors: thompson ja. J Immunol. 1996 Nov 1;157(9):4079-86. J Immunol. 1996. PMID: 8892642

9

Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.

Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PD. Yee C, et al. Among authors: thompson ja. J Exp Med. 2000 Dec 4;192(11):1637-44. doi: 10.1084/jem.192.11.1637. J Exp Med. 2000. PMID: 11104805 Free PMC article.

10

Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.

Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PD. Yee C, et al. Among authors: thompson ja. Proc Natl Acad Sci U S A. 2002 Dec 10;99(25):16168-73. doi: 10.1073/pnas.242600099. Epub 2002 Nov 11. Proc Natl Acad Sci U S A. 2002. PMID: 12427970 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,070 results

Search Page